BCL-2 family protein expression in human malignant glioma: A clinical- pathological correlative study

Journal of the Neurological Sciences

Volumn 155, Issue 1, 1998, Pages 68-75

  Rieger, Lorenz ^a   Weller, Michael ^a   Bornemann, Antje ^a   Schabet, Martin ^a   Dichgans, Johannes ^a   Meyermann, Richard ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

BAX; BCL 2; BCL X; Malignant glioma; MCL 1; p53

Indexed keywords

NITROSOUREA; PROCARBAZINE; PROTEIN P53; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CLINICAL ARTICLE; GLIOBLASTOMA; HUMAN; IMMUNOCHEMISTRY; MULTIGENE FAMILY; OLIGODENDROGLIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR RECURRENCE;

ADOLESCENT; ADULT; AGED; BRAIN CHEMISTRY; BRAIN NEOPLASMS; GLIOMA; HUMANS; MIDDLE AGED; MULTIGENE FAMILY; PROTO-ONCOGENE PROTEINS C-BCL-2; RETINOBLASTOMA PROTEIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0032542505     PISSN: 0022510X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-510X(97)00277-3     Document Type: Article

References (40)

1. Alderson L.M., Castleberg R.L., Harsh G.R., Louis D.N., Henson J.W. Human gliomas with wild-type p53 express BCL-2. Cancer Res. 55:1995;999-1001.
2. Bögler O., Huang H.J.S., Kleihues P., Cavenee W.K. The p53 gene and its role in brain tumors. Glia. 15:1995;308-327.
3. Boise L.H., Gonzalez-Garcia M., Postema C.E.et al. BCL-X, a BCL-2 related gene that functions as a dominant regulator of apoptotic cell death. Cell. 74:1993;597-660.
4. Chou D., Miyashity T., Mohrenweiser H.W.et al. The BAX gene maps to the glioma candidate region at 19q13, but is not altered in human gliomas. Cancer Genet. Cytogenet. 88:1996;136-140.
5. Cox L.S., Lane D.P. Tumor suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. Bioessays. 17:1995;501-508.
6. Ellison D.W., Steart P.V., Bateman A.C., Pickering R.M., Palmer J.D., Weller R.O. Prognostic indicators in a range of astrocytic tumors: an immunohistochemical study with Ki-67 and p53 antibodies. J. Neurol. Neurosurg. Psychiatry. 59:1995;413-419.
7. Ellison D.W., Steart P.V., Gatter K.C., Weller R.O. Apoptosis in cerebral astrocytic tumors and its relationship to expression of the BCL-2 and p53 proteins. Neuropathol. Appl. Neurobiol. 21:1995;352-361.
8. Haffner R., Oren M. Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev. 5:1995;84-90.
9. Haldar S., Jena N., Croce C.M. Inactivation of BCL-2 by phosphorylation. Proc. Natl. Acad. Sci. USA. 92:1995;4507-4511.
10. Hall P.A., Lane D.P. p53 in tumor pathology: can we trust immunohistochemistry?-revisited! J. Pathol. 172:1994;1-4.
11. He J., Olson J.J., James C.D. Lack of p16ink4 or retinoblastoma protein (pRB), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res. 55:1995;4833-4836.
12. Henson J.W., Schnitker B.L., Correa K.M.et al. The retinoblastoma gene is involved in malignant progression of astrocytomas. Ann. Neurol. 36:1994;714-721.
13. Kerr J.F.R., Winterford C.M., Harmon B.V. Apoptosis, its significance in cancer and cancer therapy. Cancer. 73:1994;2013-2026.
14. Kouzarides T. Functions of pRb and p53: what́s the connection. Trends Cell. Biol. 5:1995;448-450.
15. Krishna M., Smith T.W., Recht L.D. Expression of BCL-2 in reactive and neoplastic astrocytes: lack of correlation with presence or degree of malignancy. J. Neurosurg. 83:1995;1017-1022.
16. Levin V.A., Silver P., Hannigan J.et al. Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int. J. Radiat. Oncol. Biol. Phys. 18:1989;321-324.
17. Levine A.J. The tumor suppressor genes. Annu. Rev. Biochem. 62:1993;623-651.
18. Levine A.J., Mommand J. Tumor suppressor genes: the p53 and retinoblastoma sensitivity genes and gene products. Biochim. Biophys. Acta. 1032:1990;119-136.
19. Louis D.N., Deimling A., Chung R.Y.et al. Comparative study of p53 gene and protein alterations in human astrocytic tumors. J. Neuropathol. Exp. Neurol. 52:1993;31-38.
20. Miyashita T., Krajewski S., Krajewska M.et al. Tumor suppressor p53 is a regulator of BCL-2 and BAX in gene expression in vitro and in vivo. Oncogene. 9:1994;1799-1805.
21. Nakasu S., Nakasu Y., Nioka H., Nakajima M., Handa J. BCL-2 protein expression in tumors of the central nervous system. Acta. Neuropathol. 88:1994;520-526.
22. Nishikawa R., Furnari F.B., Lin H.et al. Loss of p16ink4 expression is frequent in high grade gliomas. Cancer Res. 55:1995;1941-1945.
23. Reed J.C. BCL-2: prevention of apoptosis as a mechanism of drug resistance. Hematol. Oncol. Clin. North. Am. 9:1995;451-470.
24. Reed J.C., Miayashita T., Takayama S.et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J. Cell. Biochem. 60:1996;23-32.
25. Reifenberger G., Liu L., Ichimura K., Schmidt E., Collins V.P. Amplification and overexpression of the mdm2 gene in a subset of human malignant gliomas without p53 mutations. Cancer Res. 53:1993;2736-2739.
26. Reynolds J.E., Yang T., Qian L.et al. MCL-1, a member of the BCL-2 family, delays apoptosis induced by c-myc overexpression in Chinese hamster ovary cells. Cancer Res. 54:1994;6348-6352.
27. Roth W., Wagenknecht B., Grimmel C., Dichgans J., Weller M. (in press) Taxol-mediated augmentation of CD95 ligand-induced apoptosis of human malignant glioma cells is independent of p53 induction and G2/M cell cycle arrest. Br. J. Cancer.
28. Schiffer D., Cavalla P., Migheli A., Giordana M.T., Chiado-Piat L. BCL-2 distribution in neuroepithelial tumors: an immunohistochemical study. J. Neurooncol. 27:1996;101-109.
29. Schmidt E.E., Ichimura K., Reifenberger G., Collins V.P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res. 54:1994;6321-6324.
30. Shapiro W.R., Green S.B., Burger P.C.et al. Randomized trial of three chemotherapy regiments and two radiotherapy regiments in postoperative treatment of malignant glioma. Brain Tumor Cooperative Group Trial 8001. J. Neurosurg. 71:1989;1-9.
31. Ueki K., Ono Y., Henson J.W., Efird J.T., von Deimling A., Louis D.N. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res. 56:1996;150-153.
32. Van Meir E.G., Kikuchi T., Tada M.et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 54:1994;649-652.
33. Wagenknecht B., Trepel M., Von Deimling A., et al. (in press). p53 accumulation promotes dephosphorylation and proteolytic cleavage of retinoblastoma protein in human malignant glioma cells. Cell. Physiol. Biochem.
34. Waldman T., Kinzler K.W., Vogelstein B. p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res. 55(22):1995;5187-5190.
35. Weller M., Frei K., Groscurth P., Krammer P.H., Yonekawa Y., Fontana A. Anti-Fas/APO-1 antibody-mediated apoptosis of cultured human glioma cells. J. Clin. Invest. 94:1994;954-964.
36. Weller M., Malipiero U., Aguzzi A., Reed J.C., Fontana A. Protooncogene BCL-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J. Clin. Invest. 95:1995;2633-2643.
37. Weller M. Genetic regulation and therapeutic modulation of apoptosis in human malignant glioma. Cell. Physiol. Biochem. 6:1997;376-380.
38. Weller M., Schmidt C., Roth W., Dichgans J. Chemotherapy of human malignant glioma: prevention of efficacy by dexamethasone? Neurology. 48:1997;1704-1709.
39. Zha J., Harada H., Yang E., Jockel J., Korsmeyer S.J. Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 124-3-3 not BCL-XL. Cell. 87:1996;619-628.
40. Zhou P., Liping Q., Kozopas K.M., Craig R.W. MCL-1, a BCL-2 family member, delays the death of hematopoietic cells under a variety of apoptosis-inducing conditions. Blood. 89:1997;630-643.